Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai Files for Gene Test for Companion Diagnostic to Lynparza
April 1, 2019
- Takeda Spin-Off Startup Chordia Raises 3 Billion Yen to Fund Oncology R&D
April 1, 2019
- Sumitomo Dainippon Carves Out Pain Program, 2025 Launch Eyed for Rare Pediatric Disease
March 29, 2019
- Janssen Files Stelara for Ulcerative Colitis in Japan
March 29, 2019
- Ono Seeks Japan Approval for Opdivo in MSI-H Colorectal Cancer
March 29, 2019
- Pfizer Japan to Stop Hiring Smokers
March 29, 2019
- Astellas/Seattle Genetics’ ADC Succeeds in PII Urothelial Cancer Study; US Filing Set for 2nd Half of 2019
March 29, 2019
- After 70% Pricing OK’ed for Biosame, Nesp Biosimilar Developers Stay Pat on November Listing Plans
March 28, 2019
- Ono Hooks Up with UK Charities in Cancer Immunotherapy
March 28, 2019
- Daiichi Sankyo Kicks Off Asia PIII for Mirogabalin
March 28, 2019
- Chugai’s SMA Drug Risdiplam Gets Orphan Status
March 28, 2019
- JSR Enters Strategic Partnership with Dutch Institute in Oncology Field
March 28, 2019
- Astellas’ Vasomotor Symptom Treatment Fezolinetant Smashes Primary Goals in US PIIb Study
March 28, 2019
- Kymriah OK’ed, Novartis Says It’s Not Up for Outcome-Based Pricing in Japan
March 27, 2019
- AnGes Bags Conditional Approval for Collategene Gene Therapy
March 27, 2019
- Fujifilm, NCC Join Hands for I/O Research, Combining Liposomes with Immune Checkpoint Inhibitors
March 27, 2019
- Boehringer’s Ofev Gets Orphan Status for ILD in Systemic Sclerosis
March 27, 2019
- Novartis Snags Japan Approval for CAR-T Therapy Kymriah
March 26, 2019
- Novartis to Tap Disease Registry for Kymriah’s All-Case PMS: Exec
March 26, 2019
- SanBio to Move Ahead with SB623 Development in Stroke after PII Miss: President
March 26, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…